초록

The invention relates to prophylactic and therapeutic vaccines for protecting individuals against metastatic colorectal cancer and for treating individuals who are suffering from metastatic colorectal cancer.

대표청구항 ▼

1. A vaccine composition comprising a viral expression vector that comprises a nucleic acid molecule that fully encodes a protein that comprises the extracellular domain of the human ST receptor protein wherein said viral vector is a recombinant virus. 2. The vaccine composition of claim 1 wherein t

1. A vaccine composition comprising a viral expression vector that comprises a nucleic acid molecule that fully encodes a protein that comprises the extracellular domain of the human ST receptor protein wherein said viral vector is a recombinant virus. 2. The vaccine composition of claim 1 wherein the protein fully encoded by the nucleic acid molecule comprises the human ST receptor protein. 3. A method of treating an individual who has metastasized colorectal cancer comprising the step of administering to such an individual a therapeutically effective amount of a vaccine composition of claim 1. 4. The vaccine composition of claim 2 wherein the protein fully encoded by the nucleic acid molecule consists of the human ST receptor protein. 5. The vaccine composition of claim 1 wherein said viral vector is a recombinant vaccinia virus. 6. The method of claim 3 wherein the protein comprises the human guanylyl cyclase C protein. 7. The method of claim 3 wherein the protein consists of the human guanylyl cyclase C protein. 8. The method of claim 3 wherein said viral vector is a recombinant vaccinia virus. 9. The method of claim 3 wherein said viral vector is a recombinant adenovirus virus. 10. A method of treating an individual who has been identified as being susceptible to metastasized colorectal cancer comprising the step of administering to such an individual a prophylactically effective amount of a vaccine composition of claim 1. 11. The method of claim 10 wherein the protein consists of the human guanylyl cyclase C protein. 12. The method of claim 10 wherein said viral vector is a recombinant vaccinia virus. 13. The method of claim 10 wherein said viral vector is a recombinant adenovirus virus. 14. The method of claim 3 wherein the individual has been previously been diagnosed with colorectal cancer. 15. The vaccine composition of claim 1 wherein said viral vector is a recombinant adenovirus vector. 16. The method of claim 10 wherein the protein comprises the human guanylyl cyclase C protein. 17. The method of claim 10 wherein the individual has been previously been diagnosed with colorectal cancer. 18. The vaccine composition of claim 5 wherein the protein fully encoded by the nucleic acid molecule comprises the human ST receptor protein. 19. The vaccine composition of claim 18 wherein the protein fully encoded by the nucleic acid molecule consists of the human ST receptor protein. 20. The vaccine composition of claim 6 wherein the protein fully encoded by the nucleic acid molecule comprises the human ST receptor protein. 21. The vaccine composition of claim 20 wherein the protein fully encoded by the nucleic acid molecule consists of the human ST receptor protein. 22. The vaccine composition of claim 7 wherein the protein fully encoded by the nucleic acid molecule comprises the human ST receptor protein. 23. The vaccine composition of claim 22 wherein the protein fully encoded by the nucleic acid molecule consists of the human ST receptor protein. 24. The vaccine composition of claim 8 wherein the protein fully encoded by the nucleic acid molecule comprises the human ST receptor protein. 25. The vaccine composition of claim 24 wherein the protein fully encoded by the nucleic acid molecule consists of the human ST receptor protein. 26. The vaccine composition of claim 9 wherein the protein fully encoded by the nucleic acid molecule comprises the human ST receptor protein. 27. The vaccine composition of claim 26 wherein the protein fully encoded by the nucleic acid molecule consists of the human ST receptor protein. 28. The vaccine composition of claim 13 wherein the protein fully encoded by the nucleic acid molecule comprises the human ST receptor protein. 29. The vaccine composition of claim 28 wherein the protein fully encoded by the nucleic acid molecule consists of the human ST receptor protein.